Nyxoah, a medical tech company specializing in Obstructive Sleep Apnea (OSA) solutions, announced a proposed underwritten public offering of ordinary shares in the U.S. and possibly private sales in the EU. The offering aims to raise funds for expanding commercialization in the U.S., advancing research and development of its Genio system, and supporting clinical studies and collaborations. The offering is subject to market conditions and includes an option for underwriters to buy additional shares. Proceeds will also support general corporate purposes such as working capital and potential acquisitions. This move follows Nyxoah's recent FDA approval and CE marking for its Genio system, positioning the company for growth in key markets.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
